Erythromycin
Safety
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
30 Active assets in the Safety cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bortezomib Shandong Provincial Hospital | Phase 4 | BB |
Gemtuzumab Ozogamicin Pfizer | Phase 4 | BB |
Sodium Oligomannate First Affiliated Hospital Xi'an Jiaotong University | Phase 4 | B |
Namenda First Affiliated Hospital Xi'an Jiaotong University | Phase 4 | B |
cc-5013 Shandong Provincial Hospital | Phase 4 | B |
View all 48 →
Same molecule, other indications
Erythromycin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →